Aprea Therapeutics, Inc. (NASDAQ:APRE) Sees Large Increase in Short Interest

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the target of a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 29,000 shares, an increase of 90.8% from the October 15th total of 15,200 shares. Based on an average daily trading volume, of 21,900 shares, the days-to-cover ratio is currently 1.3 days. Currently, 0.6% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Aprea Therapeutics in a research report on Thursday, October 24th. Wedbush reissued an “outperform” rating and set a $11.00 price objective on shares of Aprea Therapeutics in a research note on Tuesday, August 13th.

Aprea Therapeutics Stock Down 2.6 %

APRE stock opened at $3.43 on Wednesday. The business has a 50 day moving average of $3.34 and a 200 day moving average of $3.94. The firm has a market cap of $18.62 million, a PE ratio of -1.25 and a beta of 0.97. Aprea Therapeutics has a twelve month low of $2.15 and a twelve month high of $8.85.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.11. Aprea Therapeutics had a negative return on equity of 56.72% and a negative net margin of 1,029.50%. The firm had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.45 million. On average, research analysts expect that Aprea Therapeutics will post -2.74 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Aprea Therapeutics news, Director Marc Duey bought 30,000 shares of Aprea Therapeutics stock in a transaction dated Wednesday, October 16th. The shares were purchased at an average cost of $4.39 per share, with a total value of $131,700.00. Following the completion of the purchase, the director now owns 240,113 shares of the company’s stock, valued at approximately $1,054,096.07. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Bernd R. Seizinger bought 10,000 shares of Aprea Therapeutics stock in a transaction on Friday, October 11th. The shares were purchased at an average price of $2.68 per share, for a total transaction of $26,800.00. Following the acquisition, the director now owns 44,730 shares of the company’s stock, valued at approximately $119,876.40. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Marc Duey bought 30,000 shares of the stock in a transaction dated Wednesday, October 16th. The stock was purchased at an average price of $4.39 per share, with a total value of $131,700.00. Following the purchase, the director now owns 240,113 shares in the company, valued at $1,054,096.07. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 42,290 shares of company stock worth $165,096. 12.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Dimensional Fund Advisors LP bought a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned approximately 0.20% of Aprea Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.